(Q37495579)

20 August 2017

title

Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience (English)

1 reference

20 August 2017

1 reference

Derek G Power

1

1 reference

20 August 2017

Manish A Shah

2

1 reference

20 August 2017

Timothy R Asmis

3

1 reference

20 August 2017

Joaquin J Garcia

4

1 reference

20 August 2017

Nancy E Kemeny

5

1 reference

20 August 2017

publication date

26 May 2009

1 reference

Investigational New Drugs

20 August 2017

published in

1 reference

20 August 2017

volume

28

1 reference

20 August 2017

issue

3

1 reference

20 August 2017

page(s)

353-360

1 reference

Bleomycin in testicular cancer: will pharmacogenomics improve treatment regimens?

20 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-009-9268-Y

Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer

21 January 2018

1 reference

12 December 2020

High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history

1 reference

12 December 2020

Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.

1 reference

12 December 2020

Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature

1 reference

12 December 2020

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

12 December 2020

Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab

1 reference

12 December 2020

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

1 reference

12 December 2020

Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration?

1 reference

12 December 2020

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

1 reference

12 December 2020

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

12 December 2020

Drug Insight: panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer

1 reference

12 December 2020

Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer

1 reference

12 December 2020

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

1 reference

12 December 2020

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

1 reference

12 December 2020

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

12 December 2020

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

12 December 2020

Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study.

1 reference

12 December 2020

Cetuximab for the treatment of colorectal cancer.

1 reference

12 December 2020

Panitumumab monotherapy in patients with metastatic colorectal cancer and cetuximab infusion reactions: a series of four case reports

1 reference

12 December 2020

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

1 reference

12 December 2020

Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma

1 reference

12 December 2020

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

12 December 2020

Six cases of treatment with panitumumab in patients with severe hypersensitivity reactions to cetuximab.

1 reference

12 December 2020

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

1 reference

12 December 2020

Reporting results of cancer treatment

1 reference

12 December 2020

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

1 reference

12 December 2020

Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil

1 reference

12 December 2020

Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil

1 reference

12 December 2020

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

1 reference

12 December 2020

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

12 December 2020

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

1 reference

12 December 2020

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

1 reference

12 December 2020

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

12 December 2020

Management of severe infusion reactions after cetuximab

1 reference

12 December 2020

10.1007/S10637-009-9268-Y

Identifiers

DOI

1 reference

20 August 2017

1 reference